[Anticoagulant therapy in patients with permanent atrial fibrillation - evidence based medicine and clinical practice]

Autor: Ivona Božić, Vesna Čapkun, Dorotea Božić, Svjetlana Karabuva, Krešimir Čaljkušić, Gorana Trgo, Vedran Carević, Damir Fabijanić
Rok vydání: 2013
Předmět:
Male
Evidence-Based Medicine
Aspirin
Anticoagulants
Hemorrhage
Atrial fibrillation – complications
drug therapy
Risk assessment – methods
Anticoagulants – therapeutic use
adverse effects
Cerebral infarction – etiology
prevention and control
Thromboembolism – etiology
prevention and control
Hemorrhage – etiology
prevention and control
Warfarin – therapeutic use
adverse effects
Aspirin – therapeutic use
adverse effects
Evidence – based medicine
Stroke
Cross-Sectional Studies
Risk Factors
Thromboembolism
Atrial Fibrillation
Humans
Female
Prospective Studies
Warfarin
Fibrilacija atrija – komplikacije
farmakoterapija
Antikoagulansi – terapijska primjena
neželjeni učinci
Procjena rizika – metode
Moždani infarkt – etiologija
prevencija
Tromboembolija – etiologija
prevencija
Krvarenje – etiologija
prevencija
Varfarin – terapijska primjena
neželjeni učinci
Aspirin – terapijska primjena
neželjeni učinci
Medicina utemeljena na dokazima
Anticoagulant therapy
atrial fibrillation
Aged
Zdroj: Liječnički vjesnik
Volume 135
Issue 5-6
ISSN: 0024-3477
1849-2177
Popis: Cilj istraživanja bio je procijeniti usklađenost propisivanja tromboprofilaktičkog liječenja u bolesnika s permanentnom atrijskom fibrilacijom (pAF) s kliničkim smjernicama Europskoga kardiološkog društva. U prospektivno presječno istraživanje susljedno su uključena 674 bolesnika (59% muškaraca) otpuštenih s kardiološkog odjela s dijagnozom pAF. Težina tromboembolijskog (TE) rizika procijenjena je CHA2DS2-VASc-sustavom, a rizik od krvarenja HAS-BLED-sustavom. U skupinu velikog TE rizika klasificirano je 578 (86%), umjerenog 57 (8%), a malog 39 (6%) bolesnika. Tromboprofilaksa je primijenjena u 601 (89%) bolesnika: varfarin u 310 (46%), acetilsalicilna kiselina u 258 (38%), a klopidogrel u 33 (5%). Varfarin je propisan u 47% bolesnika velikog, 49% bolesnika umjerenog te u 26% bolesnika malog TE rizika (P=0,03), a acetilsalicilna kiselina u 39% bolesnika malog, 39% bolesnika umjerenog i 38% bolesnika velikog TE rizika (P=0,998). Acetilsalicilna kiselina (P
Objective of study was to assess the concordance of the tromboprophylactic treatment in patients with permanent atrial fibrillation (pAF) with guidelines of the European Society of Cardiology. Prospective cross-sectional study consecutivelly included 674 patients (400 Š59%Ć male) discharged from cardiology department with the diagnosis pAF. The thromboembolic risk (TE) has been established according to CHA2DS2-VASc score, whereas the bleeding risk has been assessed according to HAS-BLED score. 578 (86%) belonged to the group of high, 57 (8%) to the group of moderate, and 39 (6%) patients to the group of low TE risk. 601 (89%) patients received thromboprophylaxis: 310 (46%) warfarin, 258 (38%) acetylsalicylic acid, and 33 (5%) patients clopidogrel. Warfarin has been prescribed to 47% of patients with high, 49% of patients with moderate and to 26% of patients with low TE risk (P=0.03). Acetylsalicylic acid (ASA) has equally been prescribed to patients of all TE risk groups: low, moderate and high (39% vs. 39% vs. 38%; P=0.998). ASA (P
Databáze: OpenAIRE
Externí odkaz: